Lansoprazole

Highest phase reached

Approved

www.ebi.ac.uk

Drug type

Small molecule

www.ebi.ac.uk

First approval year

1995

www.ebi.ac.uk

First approval year: 1995
www.ebi.ac.uk

Listing at source: Listed

Highest phase reached: Approved
www.ebi.ac.uk

Drug type: Small molecule
www.ebi.ac.uk

Drug name: Lansoprazole
www.ebi.ac.uk

Molecular weight: 369.37
www.ebi.ac.uk

Structure (SMILES): Cc1c(OCC(F)(F)F)ccnc1C[S+]([O-])c1nc2ccccc2[nH]1
www.ebi.ac.uk

lansoprazole
Lansoprazole
lansoprazole component of prevpac
Lansoprazole component of prevpac
opiren
Opiren
prevacid
Prevacid
prevacid 24 hr
Prevacid 24 hr
prevacid delayed release
Prevacid delayed release
prevacid iv
Prevacid iv
prevacid solutab
Prevacid solutab
zoton
Zoton

(±)-Lansoprazole
a 65006
A-65006
ag 1749
AG-1749
agopton
Agopton
budesonide plus prevacid
lansoprazol
Lansoprazol
lansoprazole
Lansoprazole
Lansoprazole [EP MONOGRAPH]
Lansoprazole [HSDB]
lansoprazole [INN]
Lansoprazole [JAN]
Lansoprazole [MART.]
Lansoprazole [MI]
Lansoprazole [ORANGE BOOK]
Lansoprazole [USAN]
Lansoprazole [USP MONOGRAPH]
Lansoprazole [USP-RS]
Lansoprazole [VANDF]
Lansoprazole [WHO-DD]
lansoprazole ep monograph

And 34 more, listed on the interactive page.

CAS registry numbers

103577-45-3

ChEMBL ID: CHEMBL480
www.ebi.ac.uk

InChIKey: MJIHNNLFOKEZEW-UHFFFAOYSA-N
www.ebi.ac.uk

PubChem compound IDs

3883

RxNorm IDs (RxCUI)

17128

FDA ingredient codes (UNII)

0K5C5T2QPG

A02BC03
A02BC53

Sources for recorded values

www.ebi.ac.uk

Applicant: TAKEDA PHARMS USA
Approval date: 10 May 1995
Application number: NDA020406

Patents: 2
Designations: 0
Earliest recorded loss of exclusivity: 21 Apr 2036
First in class: No
Fast track: No
Breakthrough designation: No
Orphan designation: No
Priority review: No
Orphan exclusivity: No
Accelerated approval: No
Availability: Over the counter

Pharmacology name: lansoprazole
Type: Synthetic organic
Drug name stem: -prazole
Approval recorded by Guide to Pharmacology: Yes

Administration routes

Oral
Parenteral

Mechanism
Potassium-transporting ATPase inhibitor
Action type
Inhibitor
Target
Potassium-transporting ATPase
Protein identifier
P20648
Mechanism
Potassium-transporting ATPase inhibitor
Action type
Inhibitor
Target
Potassium-transporting ATPase
Protein identifier
P51164

Open Targets mechanisms

Mechanism
Potassium-transporting ATPase inhibitor
Action type
Inhibitor
Target
Potassium-transporting ATPase

DrugCentral mechanisms

Action type
Inhibitor
Gene symbol
ATP4A|ATP4B
Protein identifier
P20648|P51164
Organism
Homo sapiens
Target development level
Clinical

Condition
Leukemia, Lymphocytic, Chronic, B-Cell
Highest recorded phase
2
Condition identifier
EFO:0000095
Subject identifier
D015451
Condition
Gastritis
Highest recorded phase
3
Condition identifier
EFO:0000217
Subject identifier
D005756
Condition
Lymphoma
Highest recorded phase
3
Condition identifier
EFO:0000574
Subject identifier
D008223
Condition
Neoplasms
Highest recorded phase
1
Condition identifier
EFO:0000616
Subject identifier
D009369
Condition
Idiopathic Pulmonary Fibrosis
Highest recorded phase
3
Condition identifier
EFO:0000768
Subject identifier
D054990
Condition
Pain
Highest recorded phase
1
Condition identifier
EFO:0003843
Subject identifier
D010146
Condition
Premature Birth
Highest recorded phase
2
Condition identifier
EFO:0003917
Subject identifier
D047928
Condition
Gastroesophageal Reflux
Highest recorded phase
4
Condition identifier
EFO:0003948
Subject identifier
D005764
Condition
Eosinophilic Esophagitis
Highest recorded phase
2
Condition identifier
EFO:0004232
Subject identifier
D057765
Condition
Gout
Highest recorded phase
3
Condition identifier
EFO:0004274
Subject identifier
D006073
Condition
Duodenal Ulcer
Highest recorded phase
4
Condition identifier
EFO:0004607
Subject identifier
D004381
Condition
Pseudomyxoma Peritonei
Highest recorded phase
2
Condition identifier
EFO:0007456
Subject identifier
D011553
Condition
Stomach Ulcer
Highest recorded phase
4
Condition identifier
EFO:0009454
Subject identifier
D013276
Condition
Rectal Neoplasms
Highest recorded phase
2
Condition identifier
EFO:1000657
Subject identifier
D012004
Condition
Helicobacter Infections
Highest recorded phase
3
Condition identifier
EFO:1000961
Subject identifier
D016481
Condition
Esophagitis, Peptic
Highest recorded phase
3
Condition identifier
EFO:1001095
Subject identifier
D004942
Condition
Laryngopharyngeal Reflux
Highest recorded phase
1
Condition identifier
EFO:1001355
Subject identifier
D057045
Condition
Peptic Ulcer
Highest recorded phase
4
Condition identifier
HP:0004398
Subject identifier
D010437
Condition
Heartburn
Highest recorded phase
4
Condition identifier
MONDO:0002268
Subject identifier
D006356
Condition
Uterine Cervical Neoplasms
Highest recorded phase
2
Condition identifier
MONDO:0002974
Subject identifier
D002583
Condition
Diabetes Mellitus, Type 1
Highest recorded phase
3
Condition identifier
MONDO:0005147
Subject identifier
D003922
Condition
Osteoarthritis
Highest recorded phase
3
Condition identifier
MONDO:0005178
Subject identifier
D010003
Condition
Breast Neoplasms
Highest recorded phase
3
Condition identifier
MONDO:0007254
Subject identifier
D001943
Condition
Cystic Fibrosis
Highest recorded phase
1
Condition identifier
MONDO:0009061
Subject identifier
D003550
Condition
Endometrial Neoplasms
Highest recorded phase
2
Condition identifier
MONDO:0011962
Subject identifier
D016889

Condition identifier
EFO_0000095
Highest recorded phase
2
Condition identifier
EFO_0000217
Highest recorded phase
3
Condition identifier
EFO_0000616
Highest recorded phase
1
Condition identifier
EFO_0000768
Highest recorded phase
3
Condition identifier
EFO_0003764
Condition identifier
EFO_0003913
Condition identifier
EFO_0003913
Highest recorded phase
4
Condition identifier
EFO_0003917
Highest recorded phase
2
Condition identifier
EFO_0003948
Condition identifier
EFO_0004232
Highest recorded phase
2
Condition identifier
EFO_0004274
Highest recorded phase
3
Condition identifier
EFO_0004607
Condition identifier
EFO_0005769
Condition identifier
EFO_0007415
Condition identifier
EFO_0007456
Highest recorded phase
2
Condition identifier
EFO_0008572
Condition identifier
EFO_0009454
Condition identifier
EFO_0020925
Condition identifier
EFO_0020925
Highest recorded phase
4
Condition identifier
EFO_1000270
Highest recorded phase
2
Condition identifier
EFO_1000961
Highest recorded phase
3
Condition identifier
EFO_1000985
Condition identifier
EFO_1001095
Highest recorded phase
3
Condition identifier
EFO_1001355
Highest recorded phase
1
Condition identifier
EFO_1001461
Highest recorded phase
1

And 40 more, listed on the interactive page.

Event
acute kidney injury
Reports
1,772
Reporting signal score
2,467.11
Event
agranulocytosis
Reports
245
Reporting signal score
283.116
Event
cholestasis
Reports
267
Reporting signal score
319.977
Event
chronic kidney disease
Reports
2,737
Reporting signal score
10,077
Event
colitis microscopic
Reports
286
Reporting signal score
825.806
Event
drug reaction with eosinophilia and systemic symptoms
Reports
318
Reporting signal score
352.546
Event
end stage renal disease
Reports
642
Reporting signal score
2,255.03
Event
eosinophilia
Reports
220
Reporting signal score
256.996
Event
gastrooesophageal reflux disease
Reports
347
Reporting signal score
298.835
Event
hepatocellular injury
Reports
309
Reporting signal score
391.619
Event
hypertensive nephropathy
Reports
55
Reporting signal score
206.122
Event
hypocalcaemia
Reports
359
Reporting signal score
547.933
Event
hypomagnesaemia
Reports
505
Reporting signal score
1,106.04
Event
hyponatraemia
Reports
1,171
Reporting signal score
1,888.24
Event
injection site pain
Reports
2
Reporting signal score
167.401
Event
nephrogenic anaemia
Reports
85
Reporting signal score
258.901
Event
nephropathy
Reports
99
Reporting signal score
180.802
Event
rebound acid hypersecretion
Reports
115
Reporting signal score
516.624
Event
renal failure
Reports
873
Reporting signal score
1,018.07
Event
renal haemangioma
Reports
52
Reporting signal score
239.092
Event
renal impairment
Reports
286
Reporting signal score
177.007
Event
renal injury
Reports
646
Reporting signal score
2,094.99
Event
subacute cutaneous lupus erythematosus
Reports
137
Reporting signal score
366.533
Event
tubulointerstitial nephritis
Reports
382
Reporting signal score
695.336

NCT00149084
clinicaltrials.gov
NCT00239551
clinicaltrials.gov
NCT00762359
clinicaltrials.gov
NCT00787254
clinicaltrials.gov
NCT01452711
clinicaltrials.gov
NCT01452750
clinicaltrials.gov
NCT01452763
clinicaltrials.gov
NCT01456247
clinicaltrials.gov
NCT01456260
clinicaltrials.gov
NCT02761512
clinicaltrials.gov
NCT03050307
clinicaltrials.gov
NCT05448001
clinicaltrials.gov
NCT01452724
clinicaltrials.gov
NCT03050359
clinicaltrials.gov
NCT05010954
clinicaltrials.gov
NCT01061437
clinicaltrials.gov
NCT01131026
clinicaltrials.gov
NCT01481844
clinicaltrials.gov
NCT01505127
clinicaltrials.gov
NCT02892409
clinicaltrials.gov
NCT03317223
clinicaltrials.gov
NCT03498456
clinicaltrials.gov
NCT04167670
clinicaltrials.gov
NCT05861687
clinicaltrials.gov
NCT05933031
clinicaltrials.gov

And 58 more, listed on the interactive page.

Dose: 1 capsule
Route: Oral
How often: Once daily

Do not crush or chew capsules
Swallow whole

Hydrogen bond acceptors: 4
Hydrogen bond donors: 1
Polar surface area: 73.86
Calculated partition coefficient (ALogP): 3.52
Calculated partition coefficient (XLogP): 2.8
Prodrug: No
Chirality: Racemic
Inorganic: No
Rule-of-five violations: 0
Rotatable bonds: 5
Heavy atoms: 25
Molecular formula: C16H14F3N3O2S
Monoisotopic mass: 369.07588236
Natural product: No

0093-3008
0093-3009
0093-7350
0093-7351
0378-6981
0378-6982
0378-8015
0378-8030
0904-6662
16714-186
27241-019
27241-020
31722-570
31722-571
33342-310
33342-311
43598-561
48433-051
51079-121
51407-324
55111-398
55111-399
60687-111
60687-123
63187-152

And 57 more, listed on the interactive page.

Recorded assays: 4,170
Active assays: 216

Confirmatory
Other
Screening
Summary

Anti-Ulcer Agents
id.nlm.nih.gov
Proton Pump Inhibitors
id.nlm.nih.gov

These details could not be displayed.

Related records

Trials (188)

13-C Urea Breath Test Using BreathID System and PPIs (Proton Pump Inhibitors)
A "Screen and Treat" Helicobacter Pylori Eradication Trial in Adolescents in Three Regions of Chile
A Clinical Trial of Proton Pump Inhibitors to Treat Children With Chronic Otitis Media With Effusion
A Clinical Trial to Evaluate the Safety and Tolerability of Dexlansoprazole Injection in Healthy Chinese Adults（Part 2）
A Comparison of High-dose Dual Therapy and Half-dose Clarithromycin-containing Bismuth Quadruple Therapy for H.P Eradication in Elderly Patients
A Comparison of Safety and Treatment in Subjects With Osteoarthritis Taking Low Dose Aspirin
A Crossover Study to Assess the Drug-drug Interaction of Acid Reducing Agent(s) on the Pharmacokinetics of a Single Oral Dose of Lumicitabine (JNJ-64041575) in Healthy Adult Participants
A Multicenter, Randomized, Double Blind, Double Dummy, Parallel-Group Efficacy Study Comparing 8 Weeks of Treatment With Esomeprazole Magnesium (40mg qd) to Lansoprazole (30mg qd) for the Healing of Erosive Esophagitis in Patients With Moderate or Severe Erosive Esophagitis
A Proof of Concept Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer
A Proof of Concept, Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Study of Gastroesophageal Reflux Disease Therapy.
A Randomized, Open-Label, Comparative 3-Way Treatment Crossover Study of 24-Hour Intragastric pH Profile of Once Daily Oral Administration of Esomeprazole 40mg, Lansoprazole 30mg, and Pantoprazole 40mg at Steady State in NSAID-Using Patients
A Safety and Efficacy Study of Lansoprazole in Preventing Aspirin-Induced Gastric and Duodenal Ulcers
A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Maintenance of Healing in Participants With Healed Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)
A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole
A Study of LY2940680 in Healthy Participants
A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants.
A Study to Assess the Effects of Acid-Reducing Agent(s) on JNJ-64417184 in Healthy Participants
A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-212-A and AD-2121
A Study to Evaluate REbamiPide as an Adjuvant Regimen to Heal erosIve Reflux Esophagitis

Approved for (5)

Duodenal ulcer
Dyspepsia
Gastric ulcer
Gastroesophageal reflux disease
Peptic ulcer disease

In development for (19)

Asthma Phase 3
B-cell chronic lymphocytic leukemia Phase 2
Breast cancer Phase 3
Cervical cancer Phase 2
Cystic fibrosis Phase 1
Endometrial cancer Phase 2
Eosinophilic esophagitis Phase 2
Gastric diffuse large B-cell lymphoma Phase 2
Gastritis Phase 3
Gout Phase 3
Helicobacter pylori infectious disease Phase 3
Idiopathic pulmonary fibrosis Phase 3
Lymphoma Phase 3
Neoplasm Phase 1
Osteoarthritis Phase 3
Peptic esophagitis Phase 3
Pseudomyxoma peritonei Phase 2
Rectal cancer Phase 2
Type 1 diabetes mellitus Phase 3

Targets (2)

ATP4A Potassium-transporting ATPase inhibitor
ATP4B Potassium-transporting ATPase inhibitor

Lansoprazole

Development status

Names and chemistry

Brand names (18)

Other names (59)

Identifiers

ATC classification codes (2)

Regulatory information

United States

Other regulatory facts

Pharmacology

Drug classification

Administration routes

Mechanisms of action (2)

Open Targets mechanisms

DrugCentral mechanisms

Investigated indications (25)

Open Targets indications (65)

Reported adverse events (24)

Trial references (83)

Dosing

Conditions of use (2)

Chemical properties

National Drug Codes

Evidence counts

Active assay types (4)

Pharmacologic actions

Biological measurements

Related records

Trials (188)

Approved for (5)

In development for (19)

Other linked conditions (7)

Targets (2)